Tempo Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-11.
Tempo Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 11, 2026. The filing reports $14M sold. Its industry group is Biotechnology. It names Westbrook Weaver (Executive Officer, Director), Donald Griffin (Director), Biren Mehta (Director) (SEC Form D, September 11, 2026).
Sell to companies like Tempo Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Tempo Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Tempo Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in September 2026, largest first.
Get an email when Tempo Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Tempo Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Tempo Therapeutics, Inc. →Get the full cited report on Tempo Therapeutics, Inc.
What the filing shows about Tempo Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tempo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Tempo Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Tempo Therapeutics, Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $14M, on the same scale — one filing against the whole group's total, so it sits low by construction.
By form type: D ×3 · D/A ×1.
What the filing shows about Tempo Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tempo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tempo Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 4 most recent of 4 filings on CIK 0001813688, filed as Tempo Therapeutics, Inc.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in DE. Full history on sec.gov.
Westbrook Weaver is named as Executive Officer and Director on the Form D that Tempo Therapeutics, Inc. filed with the SEC on 11 September 2026, one of 5 people that filing names.
Donald Griffin is named as Director on the Form D that Tempo Therapeutics, Inc. filed with the SEC on 11 September 2026, one of 5 people that filing names.
Biren Mehta is named as Director on the Form D that Tempo Therapeutics, Inc. filed with the SEC on 11 September 2026, one of 5 people that filing names.
Steven Sands is named as Director on the Form D that Tempo Therapeutics, Inc. filed with the SEC on 11 September 2026, one of 5 people that filing names.
Eric Richman is named as Executive Officer and Director on the Form D that Tempo Therapeutics, Inc. filed with the SEC on 11 September 2026, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2026-09-11 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Tempo Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Tempo Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Tempo Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-09-07 · Biotech raises in San Diego
https://mentionfox.com/funding/tempo-therapeutics-inc-form-d-000003